London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Boston KPro, can we stay ahead of the curve?

Poster Details

First Author: J.Abad COLOMBIA

Co Author(s):                  

Abstract Details



Purpose:

To evaluate if a combination of strategies such as primary small-bore pars plana vitrectomy, primary glaucoma valve implantation, aggressive treatment of the underlying condition with immunomodulators or biologicals, preop ocular surface optimization, careful handling of postop meds to avoid collagenase activating medications, usage of topical medroxiprogesterone and oral doxycycline and vitamin C, intermitent cleansing with povidone-iodine and use of an oversized titanium backplate would improve medium term Boston Kpro performace and prognosis

Setting:

Private practice in Medellin, Colombia, South America

Methods:

All the mentioned strategies were applied to a group of patients with severe corneal disease and multiple prior corneal surgeries

Results:

Ten patients with a follow up ranging from 29 to 4 months had a preoperative VA of less than counting fingers. Postop VA was 20/80 on the average with all patients achieving VA of 20/200 or better. There were no cases of retroprosthetic membrane (RPM), endophthalmitis or keratitis. There was one case of KPro replacement (Seidel +) -no contact lens use; and one case of worsening glaucoma controlled with a second valve.

Conclusions:

The combination of several strategies aimed at increased KPro retention, decreased RPM formation, improved glaucoma control and decreased infectious complications, on the agregate seem to enhance the results and decrease the complications of this end-stage corneal surgery FINANCIAL INTEREST: NONE

Back to Poster listing